INSIGHTS ON FACILITY DESIGN

• Covid-19 Impact On Bioprocessing: PART 3 Long-Term Changes Resulting From The Pandemic

  Changes in the bio/pharmaceutical industry are being accelerated and catalyzed by the responses to the current Covid-19 pandemic. Although suppliers have proven themselves rather robust in their dealing with the pandemic, and business is continuing generally uninterrupted, there will be significant changes.

• Re-imagining Vaccine Manufacturing To Address Global Health Challenges

  In the last decade, biopharmaceutical industries have had to mobilize quickly in response to pandemics. Developing vaccines and manufacturing large doses in an emergency is often constrained by existing platforms and facility set ups. Vaccine manufacturing needs to evolve to tackle future global health challenges. Watch this webinar to learn more.

• COVID-19 Impact On Bioprocessing: PART 1 Accelerating Trends

  Because of the urgent demand for treatments, vaccines and assays, the pharmaceutical and biotech industries are experiencing disruptive, often chaotic, increased demands on resources. 

• Three Options To Viral Vector Manufacturing Capacity

  A recent Virtual Think Tank focused on the challenges and trends influencing design considerations for viral vector manufacturing facilities, and how they can impact companies developing cell and gene therapies.

• What You Need To Know Before Investing In A Bioprocessing Space

  Selecting the bioreactor that is best for your process and the dedicated space you have available requires consideration of many important factors.

• 6 Misconceptions About Automating Cell Therapy Manufacturing

  To help you move into a digitized world, here are six common misconceptions that can potentially hinder your ability to successfully execute an MES for cell therapy.

• Never Too Early To Plan For Automation

  Early platform design selections can greatly affect your future automation flexibility and ability to show compliance throughout regulatory reviews.

• Standardization Is Key To Building A Successful Global Business Strategy

  Standardized approaches to biomanufacturing can lower costs, improve outcomes and alter the landscape of the global pharmaceutical market.

• The Insource Vs. Outsource Dilemma

  Prior to making critical capacity decisions, a small biotech company completed an economic evaluation of manufacturing options to ensure it was selecting the best strategy for its manufacturing. Discover the critical elements of this analysis that may help to balance your assessment.